The Metabolism, Endocrinology & Diabetes (MEND) Division serves a primary academic mission. We pursue scientific inquiry in several general areas:
Adrenal research program
The adrenal research program includes ongoing studies which involve the analysis of the steroidogenic factor-1 transcription factor, the homozygous acd mutant gene causing adrenal dysgenesis, conditionally-dependent adrenal carcinoma that develops in mice lacking inhibin, the behavior of a variety of human adrenocortical carcinoma cell lines and the susceptibility of such cells to novel anti-tumor agents, as well as clinical studies of syndromes of steroid excess. Visit each faculty member's profile, by clicking each name below, to learn more about individual research interests.
Diabetes and obesity research
Diabetes and obesity research - current studies range broadly from pancreatic beta cell biology, pancreatic endocrine progenitor (stem) cell differentiation, selenoproteins and oxidative stress, lipid storage and lipid metabolism, insulin resistance in aging, outcomes of critically ill hyperglycemic patients, cost and efficacy analyses in the treatments of diabetes, insulin-stimulated glucose transport into tissues, and diabetic complications such as neuropathy. Visit each faculty member's profile, by clicking each name below, to learn more about individual research interests.
Faculty who conduct research in this area include:
Lynn Ang, MD, Peter Arvan, MD, PhD, Charles Burant, MD, PhD, Tae-Hwa Chun, MD, PhD, Corentin Cras-Méneur, PhD, Charles Evans, PhD, Jonathan Flak, PhD, Roma Gianchandani, MBBS, Leena Haataja, PhD, William Herman, MD, Israel Hodish, MD, PhD, Ronald Koenig, MD, Andrew Kraftson, MD, Ming Liu, MD, PhD, Malcolm Low, MD, PhD, Kara Mizokami-Stout, MD, Martin Myers, MD, PhD, Elif Oral, MD, Rodica Pop-Busui, MD, PhD, Ling Qi, PhD, Nathan Qi, PhD, Amy Rothberg, MD, Scott Soleimanpour, MD, Meng Tan, MD, James Wrobel, MD, Lei Yin, PhD
Pituitary research program
The pituitary research program involves studies of growth hormone secretion, sex steroid regulation of growth hormone secretion, and optimizing treatments of acromegaly. Visit each faculty member's profile, by clicking each name below, to learn more about individual research interests.
Studies of endocrine hypertension
Studies of endocrine hypertension range from patient-based analyses of relationships between adiposity and hypertension, roles of fat in steroid hormone metabolism, as well as animal model studies to analyze the roles of G-protein mediated signaling and PPAR nuclear receptor activation in lipid and glucose metabolism. Visit each faculty member's profile, by clicking each name below, to learn more about individual research interests.
Faculty who conduct research in this area include:
Richard Auchus, MD, PhD, J. Brian Byrd, MD, MS, Tobias Else, MD, Richard Mortensen, MD, PhD, Hwei-Ming Peng, PhD, William Rainey, PhD, Adina Turcu, MD
Thyroid research program
The thyroid research program includes studies on thyroid cancer, thyroid hormone biosynthesis defects, thyroid hormone receptors and their actions on target tissues, and the role of retinoids in development and cellular differentiation. Visit each faculty member's profile, by clicking each name below, to learn more about individual research interests.
Research Centers and Programs
Advanced training and collaborative research involving faculty, fellows, medical students, and graduate students expands the base of scientific knowledge required for cures and improved clinical outcomes. Our centers for basic research are:
Research Programs with U-M Comprehensive Cancer Center
Additional diabetes research is conducted by the below groups:
Diabetes research program in the Brehm Tower
Type 1 and type 2 diabetes, obesity, and metabolic disease research takes place on the fifth and sixth floors in the Brehm Tower, named for Bill and Delores (Dee) Brehm, providing 33,000 net square feet for research labs, systems analysis and bioinformatics offices, a "Cure Room" convening space, and related support. Their $44 million dollar gift to the University of Michigan, along with their dedication and hard work, has catalyzed a new and different framework for diabetes research that is based on laboratory and clinical discovery and collaboration. Their personal mission is to apply the tools of research and analysis to find and deliver a cure for type 1 diabetes.
The research team consists of a multidisciplinary group of world-renowned scientists who are leaders in their fields; whose focus is to understand, improve, prevent, and cure diabetes. These scientists represent the spectrum of diabetes inquiry - type 1 diabetes, diabetes management, complications of diabetes, and factors leading to type 2 diabetes, such as metabolism and obesity issues. These facets are explored in bench labs with mice and cells, as well as clinical studies with human patients. The research lab area has an open layout, where proximity to each other allows for a unique intellectual synergy and sharing of ideas and resources. The team works closely together to foster new knowledge in the lab and translate this into new therapies for patients.
Research areas include:
Type 1 Diabetes, Animal & Cell Research, Type 2 Diabetes, and Metabolism & Obesity - Peter Arvan, MD, PhD, Charles Burant, MD, PhD, Corentin Cras-Méneur, PhD, Arun Das, PhD, Charles Evans, PhD, Brigid Gregg, MD, Leena Haataja, PhD, Malcolm Low, MD, PhD, Ormond MacDougald, PhD, Anna Mathew, MD, Martin Myers, MD, PhD, David Olson, MD, PhD, Elif Oral, MD, Subramaniam Pennathur, MD, Ling Qi, PhD, Nathan Qi, PhD, Leslie Satin, PhD, Santiago Schnell, DPhil, Scott Soleimanpour, MD
Finding a cure for diabetes takes collaboration. Translating research out of the lab into improved treatments for patients takes a united front of committed scientists, clinicians, and the ongoing generosity of our donors. We have an unwavering commitment to diabetes research and care. To make a gift, please visit our online giving page.
Diabetes Complications Group
The Diabetes Complications Group is a multidisciplinary consortium of research scientists, clinicians, health professionals, and technicians dedicated to the elucidation of disease mechanisms as they relate to the complications of diabetes. Their goal is to translate the understanding of disease mechanisms (i.e., neuropathy, retinopathy, and nephropathy) into novel preventative and curative treatments for diabetic complications.